Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Ruxolitinib for Immune-related Vitiligo-like Depigmentation
NCT07725432Phase 2Active, not recruiting
- Sponsor
- University of Zurich
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib cream in Vitiligo, sponsored by University of Zurich. Primary endpoint: Facial Vitiligo Area Scoring Index 75% Improvement at 24 weeks. Started Jul 2024; status: active, not recruiting.
02
Drugs
ruxolitinib cream
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT07725432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07725432.